memori
bcell
mbc
potenti
antibodi
secret
immun
cell
differenti
matur
follow
host
exposur
pathogen
follow
differenti
mbc
remain
peripher
circul
recoveri
pois
secret
antigenspecif
antibodi
reexpos
cognat
antigen
consequ
mbc
form
founder
popul
provid
one
first
line
pathogenspecif
defens
reinfect
role
mbc
play
complic
virus
heterolog
dengu
viru
denv
exist
antigen
differ
serotyp
second
infect
differ
serotyp
mbc
initi
dengu
infect
rapidli
prolifer
secret
antibodi
mani
mbc
deriv
antibodi
crossreact
weakli
neutral
antibodi
may
recogn
epitop
conserv
across
serotyp
capac
broadli
neutral
serotyp
also
possibl
new
popul
mbc
antibodi
specif
second
viru
serotyp
need
aris
longterm
broader
immun
develop
method
interrog
track
memori
b
cell
respons
import
evalu
natur
immun
vaccin
respons
howev
low
abund
mbc
specif
pathogen
make
challeng
interrog
frequenc
specif
breadth
pathogen
interest
review
discuss
current
approach
use
interrog
memori
b
cell
immun
respons
viral
pathogen
gener
denv
specif
includ
strength
limit
futur
direct
singlecel
approach
could
help
uncov
denv
specif
mbc
antibodi
repertoir
improv
method
isol
denv
specif
monoclon
antibodi
human
peripher
blood
cell
would
allow
function
analysi
antidenv
repertoir
neutral
antibodi
respons
play
critic
role
antivir
immunitycontrol
prevent
infect
import
aim
vaccin
initi
infect
host
bcell
specif
infect
antigen
prolifer
differenti
shortliv
plasmablast
secret
antibodi
high
rate
combat
exist
infect
follow
viral
clearanc
two
distinct
layer
humor
immun
remain
protect
repeat
infect
antigenantibodi
sera
constitut
produc
long
live
plasma
cell
llpc
memori
bcell
mbc
prime
expand
secret
antibodi
upon
antigen
reexposur
llpc
termin
differenti
nondivid
cell
resid
bone
marrow
produc
antibodi
year
decad
provid
protect
repeat
infect
antigen
antibodi
typic
assess
vitro
neutral
bind
assay
mani
case
regard
correl
protect
viral
pathogen
mbc
make
second
line
antibodymedi
defens
provid
protect
rapidli
activ
prolifer
secret
antibodi
respons
cognat
antigen
regard
backup
llpcderiv
antibodi
specif
breadth
potenti
mbc
respons
increasingli
appreci
especi
regard
protect
heterogen
antigen
relat
viral
pathogen
influenza
differ
serotyp
denv
viral
escap
mutant
bcell
mbc
precursor
origin
bone
marrow
migrat
spleen
undergo
differenti
redistribut
lymph
node
await
antigen
encount
recent
work
mice
suggest
mbc
origin
low
affin
germin
center
compart
within
peripher
lymph
node
might
contribut
broadli
reactiv
ig
receptor
increas
breadth
recal
respons
mbc
form
heterogen
popul
thought
preferenti
differenti
upon
reinfect
specif
igg
mbc
favor
differenti
plasmablast
wherea
igm
mbc
preferenti
reenter
germin
center
undergo
round
affin
matur
mbc
identifi
bcell
receptor
bcr
membran
bound
immunoglobulin
ig
ident
antibodi
secret
upon
activ
upon
reinfect
recal
respons
rapid
domin
high
affin
isotyp
switch
antibodi
igg
iga
ige
depend
pathogen
recal
respons
lead
gener
new
antigenspecif
llpc
mbc
although
human
mbc
character
mani
import
viral
pathogen
includ
hiv
rsv
influenza
human
denv
mbc
deriv
antibodi
fulli
character
mosquitotransmit
denv
respons
million
symptomat
case
death
annual
make
common
seriou
vectorborn
diseas
affect
human
denv
envelop
posit
sens
rna
viru
circul
four
distinct
serotyp
denv
share
sequenc
homolog
repeat
infect
often
occur
denv
endem
regionsasia
latin
america
africa
part
oceana
popul
growth
increas
global
travel
spread
vector
led
increas
epidem
denv
infect
caus
symptom
includ
high
fever
rash
portion
patient
per
year
develop
sever
dengueref
dengu
shock
syndrom
dss
dengu
hemorrhag
fever
dhf
progress
organ
failur
death
first
infect
one
serotyp
thought
provid
lifelong
protect
serotyp
shortliv
protect
heterolog
infect
secondari
infect
differ
serotyp
lead
broader
protect
four
serotyp
come
greater
risk
seriou
diseas
acut
infect
process
antibodi
depend
enhanc
occur
subneutr
antibodi
bind
viru
facilit
uptak
cell
via
fc
receptor
mechan
subsequ
broader
immun
develop
incomplet
understood
known
immedi
follow
second
infect
antibodi
respons
contain
larg
proport
crossreact
antibodi
neutral
virus
rel
contribut
type
specif
weakli
crossneutr
broadli
neutral
antibodi
longterm
immun
unclear
may
depend
viru
matur
state
complic
hypothes
role
broadli
crossneutr
antibodi
recent
find
raut
et
al
vitro
neutral
assay
use
matur
partial
matur
tissuecultur
deriv
overestim
almost
potenc
heterotyp
neutral
antibodi
compar
neutral
potenc
fulli
matur
circul
human
deeper
understand
divers
epitopespecif
mbc
could
lead
develop
subunit
vaccin
preferenti
elicit
potent
neutral
antibodi
denv
serotyp
avoid
potenti
enhanc
antibodi
analys
human
antibodi
respons
denv
infect
tradit
character
serum
antibodi
product
llpc
viru
neutral
bind
enhanc
assay
recent
greater
focu
put
character
bcell
produc
antibodi
histor
method
interrog
antigenspecif
bcell
particularli
human
challeng
develop
howev
complex
studi
individu
popul
mbc
monoclon
antibodi
mab
produc
area
critic
import
studi
allow
better
understand
natur
human
immun
respons
pathogen
denv
expect
lead
ration
design
vaccin
sever
decad
method
interrog
antigenspecif
mbc
sever
use
function
identifi
subset
mbc
avail
respond
repeat
infect
track
mbc
prior
vaccin
booster
isol
character
human
mab
follow
natur
infect
vaccin
analyz
memoryderiv
antibodi
repertoir
recent
method
employ
denv
field
review
lead
approach
character
human
denv
mbc
evalu
strength
limit
potenti
contribut
field
summar
tabl
lda
first
use
detect
virusspecif
mbc
mice
year
ago
approach
allow
frequenc
specif
rare
antigenspecif
mbc
circul
approach
mbc
becom
antigensecret
cell
cell
enumer
elispot
describ
later
secret
antibodi
assay
antigenspecif
elisa
approach
use
determin
frequenc
viralspecif
mbc
human
follow
vaccin
natur
infect
nonspecif
stimul
human
mbc
allow
character
multipl
antigenspecif
mbc
deriv
antibodi
singl
pbmc
sampl
antibodi
contain
supernat
mbc
use
wide
rang
assay
includ
elispot
elisa
neutral
major
limit
approach
cell
immort
therefor
longev
limit
surfac
bcr
downregul
singl
antigenspecif
mbc
clone
identifi
subject
downstream
sequenc
clone
provid
sensit
specif
tool
detect
antigenspecif
mbc
first
describ
year
ago
method
quantifi
rare
b
cell
still
wide
use
today
sensit
enough
detect
singl
antigenspecif
cell
plasmablast
studi
directli
ex
vivo
mbc
must
stimul
becom
antibodysecret
cell
membranebound
antigen
enabl
bind
mab
secret
bcell
bound
antibodi
detect
use
secondari
antibodi
colorimetr
substrat
result
color
spot
membran
easili
enumer
use
imag
softwar
advanc
elispot
technolog
allow
research
detect
differ
isotyp
mbc
recogn
multipl
epitop
multipl
antigen
recent
develop
multifunct
fluorospot
assay
allow
enumer
crossreact
typespecif
denv
zika
mbc
follow
natur
infect
vaccin
allow
research
determin
serotyp
specif
singlecel
basi
rather
polyclon
level
elispot
highli
sensit
allow
enumer
rare
cell
interestfrequ
specif
antibodi
isotyp
determin
major
limit
allow
isol
downstream
analysisfunct
properti
antibodi
neutral
assess
cell
bcr
interest
sequenc
clone
mab
product
use
hybridoma
immort
mbc
first
describ
year
ago
hybridoma
made
fuse
myeloma
cell
bcell
immun
natur
infect
individu
result
hybrid
cell
secret
mab
specif
antigen
technic
advanc
made
feasibl
gener
hybridoma
human
peripher
blood
mbc
advanc
includ
expand
bcell
prior
fusion
find
new
human
myeloma
cell
fuse
improv
fusion
techniqu
includ
electr
cytofus
use
optim
techniqu
yu
et
al
fusion
effici
improv
enabl
isol
neutral
mab
rsv
influenza
human
peripher
mbc
hybridoma
technolog
wellestablish
indispens
platform
gener
highqual
mab
use
produc
mab
wide
rang
viral
antigen
includ
denv
major
advantag
approach
includ
pair
bcr
heavi
light
chain
nativ
constant
region
mab
express
allow
fcmediat
effector
function
enhanc
access
final
hybridoma
product
stabl
cultur
frozen
futur
use
one
major
limit
approach
extrem
low
fusion
effici
consequ
tradit
hybridoma
strategi
well
suit
identifi
rare
antigenspecif
mbc
circul
low
number
peripheri
immun
donor
overal
small
amount
total
b
cell
repertoir
captur
second
major
limit
challeng
make
human
rather
mous
deriv
hybridoma
work
wahala
et
al
found
human
mice
recogn
distinct
differ
epitop
denv
virion
follow
immun
mice
natur
infect
human
nearli
neutral
antibodi
found
human
natur
infect
recogn
complex
quaternari
epitop
surfac
whole
virion
contrast
denv
neutral
antibodi
respons
mice
major
neutral
antibodi
recogn
singl
domain
region
domain
iii
envelop
glycoprotein
mbc
immort
achiev
transform
peripher
mbc
use
epstein
barr
viru
ebv
express
bclxl
result
stabl
cell
line
express
bcr
surfac
secret
antibodi
make
use
tool
gener
human
mab
becom
lead
approach
character
denvspecif
mbc
human
ebv
transform
bcell
cultur
develop
steinitz
et
al
normal
human
bcell
infect
ebv
lymphotrop
herpesviru
transform
mbc
stabl
antibodi
secret
cell
line
supernat
screen
specif
antigen
choic
serial
dilut
singl
cell
enabl
method
appli
mab
product
mani
group
util
continu
util
ebv
immort
isol
human
mab
wide
varieti
human
pathogen
includ
hiv
sar
coronaviru
influenza
rsv
denv
anoth
techniqu
employ
immort
mbc
forc
express
requir
gc
format
bclxl
antiapoptot
protein
famili
express
gc
bcell
introduc
gene
peripher
blood
mbc
cultur
becom
highli
prolifer
surfac
secret
ig
bclxl
transduc
cell
express
aicda
encod
enzym
activationinduc
cytidin
deaminas
aid
level
isol
tonsil
deriv
gc
bcell
normal
express
peripher
mbc
plasma
cell
aid
mediat
somat
hypermut
shm
classswitch
recombin
csr
therefor
increas
divers
bcr
aid
function
cell
low
level
shm
observ
ig
gene
expand
bcell
cell
maintain
prolong
period
time
cultur
allow
mab
product
use
approach
research
identifi
neutral
mab
human
recogn
rsv
hepat
c
viru
influenza
denv
immort
bcell
plasmablastlik
phenotyp
secretori
membranebound
ig
make
power
tool
discoveri
character
mab
probe
bind
bcr
interest
enabl
isol
antigenspecif
bcell
polyclon
popul
immort
cell
stabl
frozen
futur
use
presenc
aid
potenti
shm
util
gener
clone
higher
lower
affin
parent
clone
allow
method
affin
matur
cultur
transform
effici
human
ebv
transform
improv
addit
tlr
agonist
typic
cpg
approach
requir
signific
number
cell
yield
cell
interest
cell
prolifer
approach
frequenc
particular
antigenspecif
mbc
enumer
use
ebvtransform
human
bcell
gener
human
hybridoma
increas
effici
much
compar
use
untransform
pbmc
therefor
investig
often
util
combin
approach
ebv
immort
follow
fusion
isol
human
denvspecif
mab
natur
infect
vaccin
donor
flow
cytometrybas
approach
use
enumer
antigen
specif
mbc
model
antigen
mice
human
howev
viral
antigenspecif
flow
cytometri
util
recent
weitkamp
use
biotinyl
denv
envelop
protein
probe
along
dual
label
streptavidin
antibodi
identifi
denv
envelopespecif
mbc
method
enabl
research
isol
denvneutr
mab
singl
donor
tabl
antigen
choic
import
denv
neutral
epitop
compris
complex
conform
structur
recapitul
simpl
linear
peptid
recombin
protein
howev
whole
virus
inher
sticki
adher
host
cell
tackl
nonspecif
bind
util
fluoresc
label
vero
cell
supernat
well
dual
label
probe
decreas
background
major
strength
approach
possibl
track
multipl
serotyp
denvspecif
mbc
prior
post
infect
vaccin
well
potenti
singl
cell
sort
antigenspecif
mbc
downstream
assay
immort
sequenc
clone
import
earli
advanc
field
human
mab
gener
advent
singlecel
rtpcr
approach
allow
sequenc
clone
character
bcr
individu
sort
mbc
approach
remain
use
popul
interest
repres
larg
proport
total
cell
popul
plasmablast
acut
infect
valid
probe
screen
approach
exist
identifi
mbc
interest
prior
sequenc
addit
gener
mab
sequenc
bcr
provid
inform
bcell
clonal
evolut
infect
groundbreak
singlecel
approach
time
resourc
intens
requir
heavi
light
chain
undergo
pcr
sequenc
clone
independ
remain
correctli
pair
transfect
express
plasmid
singlecel
approach
provid
glimps
overal
antibodi
repertoir
potenti
divers
human
high
throughput
method
captur
entir
antigenspecif
mbc
repertoir
recent
develop
pathogen
would
expect
advanc
denv
field
well
highthroughput
droplet
microfluid
approach
allow
individu
partit
singl
bcell
individu
barcod
allow
pair
sequenc
ig
heavi
light
chain
singl
b
cell
captur
within
droplet
complet
ig
librari
gener
well
approach
allow
simultan
sequenc
barcod
ig
gene
possibl
coexpress
function
gene
fulli
understand
pathogen
specif
mbc
repertoir
mab
gener
antibodi
gene
sequenc
allow
function
analysi
repertoir
anoth
high
throughput
approach
recent
use
isol
mab
human
involv
use
microfluid
partit
individu
cell
physic
link
heavi
light
mrna
perform
overlap
extens
pcr
gener
continu
heavylight
chain
amplicon
clone
yeast
display
system
fab
igg
allow
screen
antigen
specif
affin
fac
approach
research
abl
isol
broadli
neutral
antibodi
hiv
ebola
influenza
abil
fulli
interrog
mbc
respons
establish
natur
infect
viral
antigen
allow
research
durabl
comprehens
interrog
vaccin
respons
understand
differ
natur
vaccin
deriv
immun
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
